ATE438413T1 - Integrin-vermittelte arzneimittel-zielrichtung - Google Patents

Integrin-vermittelte arzneimittel-zielrichtung

Info

Publication number
ATE438413T1
ATE438413T1 AT00965901T AT00965901T ATE438413T1 AT E438413 T1 ATE438413 T1 AT E438413T1 AT 00965901 T AT00965901 T AT 00965901T AT 00965901 T AT00965901 T AT 00965901T AT E438413 T1 ATE438413 T1 AT E438413T1
Authority
AT
Austria
Prior art keywords
sub
integrin
drug targeting
cytostatic
beta
Prior art date
Application number
AT00965901T
Other languages
English (en)
Inventor
Hans-Georg Lerchen
Joerg Baumgarten
Ulf Brueggemeier
Markus Albers
Andreas Schoop
Thomas-J Schulze
Original Assignee
Markus Albers
Joerg Baumgarten
Ulf Brueggemeier
Hans-Georg Lerchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Markus Albers, Joerg Baumgarten, Ulf Brueggemeier, Hans-Georg Lerchen filed Critical Markus Albers
Application granted granted Critical
Publication of ATE438413T1 publication Critical patent/ATE438413T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
AT00965901T 1999-09-08 2000-08-28 Integrin-vermittelte arzneimittel-zielrichtung ATE438413T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39216799A 1999-09-08 1999-09-08
US60677200A 2000-06-29 2000-06-29
PCT/EP2000/008361 WO2001017563A2 (en) 1999-09-08 2000-08-28 Integrin-mediated drug targeting

Publications (1)

Publication Number Publication Date
ATE438413T1 true ATE438413T1 (de) 2009-08-15

Family

ID=27013781

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965901T ATE438413T1 (de) 1999-09-08 2000-08-28 Integrin-vermittelte arzneimittel-zielrichtung

Country Status (16)

Country Link
US (1) US20060189544A1 (de)
EP (1) EP1235595B8 (de)
JP (1) JP2003508497A (de)
CN (1) CN1402643A (de)
AT (1) ATE438413T1 (de)
AU (1) AU773781B2 (de)
BR (1) BR0013883A (de)
CA (1) CA2383981A1 (de)
DE (1) DE60042700D1 (de)
ES (1) ES2330079T3 (de)
HU (1) HUP0203899A3 (de)
MX (1) MXPA02002488A (de)
NZ (1) NZ517620A (de)
PL (1) PL354268A1 (de)
RU (1) RU2002109215A (de)
WO (1) WO2001017563A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1219305A1 (de) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Konjugate von Integrinrezeptorantagonisten und einem zytostatischen Mittel mit spezifisch spaltbaren Linkergruppen
EP1238678A1 (de) 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzymaktivierte cytostatische Prodrugverbindungen mit Integrin Liganden
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
ITRM20040241A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 20 con antagonisti delle integrine.
CN105566338B (zh) * 2014-10-08 2017-11-21 兰州大学 一种喜树碱类化合物及其制备方法和用途
CN108456154A (zh) * 2018-04-13 2018-08-28 昆明理工大学 一种n-叔丁氧羰基烃基胍的制备方法
WO2023057813A1 (en) * 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders
WO2023057814A1 (en) * 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020229A1 (en) * 1992-04-03 1993-10-14 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
AU1821397A (en) * 1995-12-21 1997-11-07 Scripps Research Institute, The Targeted therapeutic or diagnostic agents and methods of making and using same

Also Published As

Publication number Publication date
US20060189544A1 (en) 2006-08-24
BR0013883A (pt) 2002-05-07
CA2383981A1 (en) 2001-03-15
PL354268A1 (en) 2003-12-29
ES2330079T3 (es) 2009-12-04
HUP0203899A2 (hu) 2003-02-28
EP1235595B1 (de) 2009-08-05
CN1402643A (zh) 2003-03-12
EP1235595B8 (de) 2009-10-07
WO2001017563A3 (en) 2002-07-11
DE60042700D1 (de) 2009-09-17
RU2002109215A (ru) 2003-12-10
JP2003508497A (ja) 2003-03-04
WO2001017563A2 (en) 2001-03-15
HUP0203899A3 (en) 2004-09-28
NZ517620A (en) 2004-02-27
AU7648700A (en) 2001-04-10
AU773781B2 (en) 2004-06-03
MXPA02002488A (es) 2002-08-12
EP1235595A2 (de) 2002-09-04

Similar Documents

Publication Publication Date Title
NO981944D0 (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
BR0014078A (pt) Inibidores de fator xa
BR9916857A (pt) 4 heteroaril diarilaminas
SE9504661D0 (sv) New compounds
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
BR0007514A (pt) Macrolìdeos com atividade anti-inflamatória
BR9909486A (pt) Compostos calcilìticos
BR0209440A (pt) Sulfonamidas
SE9802208D0 (sv) Novel compounds
ATE438413T1 (de) Integrin-vermittelte arzneimittel-zielrichtung
BR0014294A (pt) Quinazolinonas
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
IT1270618B (it) Proteine ad attivita' antitumorale
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
SE9902056D0 (sv) An integrin heterodimer and an alpha subunit thereof
BR9814188A (pt) "agonistas de 5-ht1f"
SE9802209D0 (sv) Novel compounds
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
IT1306147B1 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
IT1261646B (it) Derivati peptidici ad attivita' citostimolante e citoprotettiva
TR200200017T2 (tr) Benzofuran türevleri
ATE397447T1 (de) Feste paroxetin enthaltende zubereitungen
TR200100801T2 (tr) Benzoilguanidin türevleri, imalatlarına yönelik yöntemler, ilaç yapımında kullanımı
ITMI20021040A1 (it) Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties